NRXPW
NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.01
+0.00%Price chart
Apr 28May 1May 6May 11May 14May 19May 22May 28
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$315682.73
MomentumView details →
1D Return
+0.00%
YTD Return
−79.94%
RSI (14)
55.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$315682.73
RSI (14)
55.0
MomentumView details →
1D Return
+0.00%
YTD Return
−79.94%
Similar companies
Latest newsMore news →
NRx Pharmaceuticals completed the first-cycle FDA review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, and submitted the sole remaining manufacturer's attestation on the vial to the FDA.19d agoNRx Pharmaceuticals, Inc. reported a Q2 2026 loss of $0.18 per share, missing the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.98 per share a year ago.21d agoNRx Pharmaceuticals completed the first-cycle FDA review of its abbreviated new drug application for preservative-free ketamine, with one remaining issue related to the product's vial connector.26d ago